Indication Global
Market Size
Pre
Clinical
Phase
Ib
Phase
IIb
Potential support for EU Conditional
Marketing Approval
Submission
Post EU
Marketing
US Phase 3
Organ failure associated with Sepsis $33B   Completed Randomized,
controlled
Phase II ongoing
Top-line data for Phase II April 24’
               
Moderate knee osteoarthritis $7B     Randomized,
controlled Phase I/II
expected Q1 2024
Top-line data for Phase I/II Q3-25’
               
End-stage knee osteoarthritis $2B   Phase I/II
ongoing
  Top-line data for Phase I/II EOQ3-24’